{"id":7713,"date":"2023-07-26T14:43:19","date_gmt":"2023-07-26T14:43:19","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=7713"},"modified":"2023-07-26T14:43:19","modified_gmt":"2023-07-26T14:43:19","slug":"nano-vaccines-induce-t-cell-immunity-and-control-of-tumour-growth","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/nano-vaccines-induce-t-cell-immunity-and-control-of-tumour-growth\/","title":{"rendered":"Nano Vaccines Induce T Cell Immunity and Control of Tumour Growth"},"content":{"rendered":"\n

The application of nanoparticle (NP) technology towards the development of vaccines for infectious diseases and cancer is advancing and has been shown to enhance the immunogenicity of some vaccine candidates. The nano-immuno activators or stimulators include inorganic NPs like iron and silica, polymeric NPs including chitosan and poly(lactic-co-glycolic) acid (PLGA), cholesterol and lipid liposomes, as well as virus-like particles.\u00a0Specially, these strategies manipulate antigen-presenting cells (APCs), and benefit the vaccination process, as a result, the nanoparticle-based platforms can be engineered to elicit appropriate downstream immune responses.\u00a0<\/p>\n\n\n\n

A recent publication by Hocheol Shin et al., 2023, evaluated the therapeutic efficacy of FAP Nano vaccines alone and in combination with an anticancer drug in ECM-rich desmo-plastic tumour models. The Immunodominant Epitope Peptides of FAP were predicted using three epitope-prediction programs. The QuickSwitch™ Quant H-2 Kb Tetramer Kit-PE<\/a> was used to accurately measure the presence of FAPPEP1-specific CD8+ T cells within the lymph nodes. The tetramer assays conducted on cells isolated from the popliteal lymph nodes unveiled a significant increase in the percentage of H-2Kb FAPPEP1 tetramer+ CD8+ T cells exclusively in the FAPPEP1-SLNP-immunised group, as compared to the untreated control group. These findings strongly suggest that FAPPEP1-SLNP immunisation effectively triggers a targeted immune response specific to FAPPEP1.<\/p>\n\n\n\n

\n
Successfully Build Tetramers With Your Specifications!<\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n
Product Code<\/strong><\/td>Product Name<\/strong> <\/td>Size<\/strong><\/td>Applications:<\/strong><\/td><\/tr>
TB-7410-K1<\/a><\/strong><\/td>QuickSwitch™ Quant H-2 Kb Tetramer Kit-PE<\/td>1 Kit<\/td>FCM<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

REFERENCES:<\/p>\n\n\n\n

    \n
  1. Hocheol Shin, Yujin Kim, and Sangyong Jon ACS Nano 2023 17 (11), 10337-10352
    DOI: 10.1021\/acsnano.3c00764ao, <\/li>\n<\/ol>\n\n\n\n

    For Research Use Only.  Not for use in diagnostic procedures.<\/em><\/p>\n\n\n\n

    Originally posted by MBL International.<\/p>\n\n\n\n

    Caltag Medsystems <\/a>is the distributor of MBL <\/a>products in the UK and Ireland. If you have any questions about these products, please contact us<\/a>.<\/a><\/p>\n\n\n\n

    <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

    Using nanoparticle technology in making vaccines for infectious diseases\/cancer is advancing & enhances the immunogenicity of some vaccine candidates.<\/p>\n","protected":false},"author":13,"featured_media":7729,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,1,202,637,15],"tags":[7,658,67,659,656,224,657],"class_list":["post-7713","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-general-information","category-infectious-disease","category-t-cells","category-tetramer","tag-cancer","tag-infectious-disease","tag-mbl-international","tag-nanoparticle","tag-t-cell-immunity","tag-tetramer","tag-tumour"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/7713","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=7713"}],"version-history":[{"count":15,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/7713\/revisions"}],"predecessor-version":[{"id":7730,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/7713\/revisions\/7730"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/7729"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=7713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=7713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=7713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}